Arlington Partners LLC Investment Activity: Q3 Analysis
This article analyzes the investment activities of Arlington Partners Llc during the quarter ending June 2026 based on disclosed holdings changes.
As reported in filings up to Arlington Partners LLC's latest data as of June 30, 2026, the investment firm has shown specific buying and selling patterns during this period.
The largest allocation in their portfolio is Vanguard FTSE Developed Markets ETF (VEA), which holds approximately $21.2 million worth of stock representing 38.35% of the total portfolio value of $54.0 million. This position saw an increase, with shares rising by 7.29% from the previous period.
In terms of specific purchases and sales during Q3 (ending June 30), Arlington Partners demonstrated activity across various sectors:
- Purchasing: The firm significantly increased its position in Zoetis Inc Common (ZTS) by acquiring shares representing a portfolio allocation increase of 0.44%. Similarly, they boosted their holdings in several other companies including Novo Nordisk A/S Spons Adr (NVO), Arthur J Gallagher & Co (AJG), Aon PLC (AON), GSK PLC ADR (GSK), Bristol-Myers Squibb Co (BMY), Medtronic PLC (MDT), and Fox Corporation Class B (FOX). These additions reflect targeted investments in specific areas.
- Selling: The firm disposed of a portion of its General Dynamics Corp (GD) holdings, reducing the allocation from 0.57% to 0.19%, which represents a significant sell as it decreased by -54.89%. They also reduced their Warner Music Group Corp Com Cl A position (WMG) from 0.56% to 0.41%, a decrease of -15.27%.
- Stable Positions: Several holdings remained unchanged during the quarter, including Vanguard Short-Term Government Bond Index Fund ETF (VGSH), Palmer Square Capital BDC Inc (PSBD), and others like Haleon PLC Spon ADS (HLN) which saw share changes but no value change reported.
Furthermore, Arlington Partners' portfolio is diversified across multiple sectors. Their largest sector allocation remains in 'Unknown', accounting for 74.52% of the total value as per their latest filing. Other significant allocations include Financial Services (4.83%), Healthcare (4.82%), Consumer Defensive (3.84%), and Technology (3.51%).
Their investment strategy appears focused on both broad exposure through ETFs like VEA, which accounts for 38.35% of the portfolio, and selective investments in individual stocks across sectors such as Healthcare and Communication Services.